Tracker › Companies › Aura Biosciences, Inc.
6 No sign of it. We found no public evidence tying Aura Biosciences, Inc.'s cuts to AI.
Every tracked 2026 layoff at Aura Biosciences, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 6/100 (Minimal) · 80% interval 4–7 · evidence grade D · US · Pharma / Chemicals
Stated reason: On the Effective Date the Company announced its organizational realignment (the “Realignment”) to streamline its operating plan and organizational structure to focus resources in ocular oncology, including its plan to minimize resource allocation towards its non-muscle invasive bladder cancer (“NMIBC”) program on a going forward basis. As part of the Realignment, the Company plans to reduce its workforce by approxima…
Why 6: Cost-cutting / efficiency · Drivers: industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.653, industry exposure 0.712, AI investment 0.0, contrary evidence 0.0 · typical Health Care & Pharma roles (no roles named)
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 4,500 workers
Health Care & Pharma · 718 workers
Health Care & Pharma · 628 workers
Health Care & Pharma · 278 workers
Health Care & Pharma · 145 workers
Health Care & Pharma · 130 workers
